If you have ever searched "how much is Wegovy without insurance," braced yourself, and closed the tab after seeing a four-figure number, this guide is for you.

How Much Is Wegovy Without Insurance? The Honest Answer

A woman with her head in her hands at a table covered in medical bills and paperwork

Maybe you are a college student on a part-time paycheck, a 24-year-old whose plan excludes weight management medications, or a parent doing the math for your teenager. The sticker shock is real: Wegovy lists at $1,349.02 per 28-day supply, more than $16,000 a year [1] [2]. Almost nobody should pay that.

List price is a negotiating number between drugmakers and insurers, not what manufacturers expect you to hand over at the pharmacy counter. In 2026, both Novo Nordisk (Wegovy, Saxenda) and Eli Lilly (Zepbound) run direct-to-patient programs that cut the cash price of a GLP-1 without insurance to a fraction of list, sometimes under $200 a month [3] [4]. Add patient assistance programs and insurance appeals, and "I could never afford this" starts turning into "this is within reach." This guide walks through every legitimate path, verified against manufacturer and government sources; the one it will not endorse, cheap compounded semaglutide, gets its warning below.

Key Takeaway

Wegovy lists at $1,349.02 per month, but almost no one needs to pay it. Manufacturer programs, savings cards, and appeals can bring your real GLP-1 cost to $149 to $449 per month, sometimes to $25 or even $0.

GLP-1 Cost Comparison: List Prices vs. What You Can Actually Pay

Here is each major GLP-1 medication's list price versus what you can pay through official manufacturer programs as of July 2026. Programs can change at any time, so confirm current pricing before you buy.

A young woman working through receipts and paperwork with a calculator and notepad
MedicationList Price (approx./month)With Commercial Insurance + Savings CardSelf-Pay Through Manufacturer ProgramApproved Ages
Wegovy pen (semaglutide injection)$1,349.02 [1]As little as $25/month (max savings $100/month) [3]$199/month for first 2 fills (through Dec 31, 2026), then $349/month; Wegovy HD $399/month [3]12+ for obesity [5]
Wegovy pill (oral semaglutide)Varies by doseAs little as $25/month [3]From $149/month [3]Adults 18+ only [3]
Zepbound (tirzepatide)About $1,086 per fill for pens [6]As low as $25 for a 1- or 3-month supply of pens [6]$299/month (2.5 mg), $399/month (5 mg), $449/month (7.5 to 15 mg with on-time refills) via LillyDirect [4]Adults 18+ only [4]
Saxenda (liraglutide)$1,349.02 [7]As little as $25, or up to $200 off per fill for up to 12 months [7]None; generic liraglutide available at lower cash prices [8]12+ for obesity [7]

NovoCare and the Wegovy Savings Offer: How to Pay Less for Semaglutide

Which Novo Nordisk program applies depends on your insurance situation.

If you have commercial insurance that covers Wegovy

The Wegovy Savings Offer works like a coupon stacked on your insurance: commercial (non-government) plans with coverage bring your cost to as little as $25 per month, with a maximum savings of $100 per month [3]. Text SAVE to 83757 or enroll on NovoCare's savings offer page, then show it to your pharmacist. If you are on a parent's employer plan, as many people ages 18 to 26 are, check this first; it is the cheapest legitimate path to Wegovy.

If you are uninsured or your plan excludes weight management medications

NovoCare Pharmacy is Novo Nordisk's direct-to-patient pharmacy for cash-paying customers; you do not need insurance or a coupon to get its prices [10]. As of July 2026, new self-pay patients pay $199 per month for their first two monthly fills of the Wegovy pen (an introductory offer through December 31, 2026), then $349 per month for standard pen doses and $399 for the high-dose Wegovy HD pen [3] [10]. The Wegovy pill, adults only, starts at $149 per month [3]. Your prescriber sends the prescription, you pay online (FSA/HSA cards accepted), and it ships free to your door [10].

For Saxenda, the daily-injection GLP-1 also FDA-approved for ages 12 and up, eligible patients can pay as little as $25 or save up to $200 per fill for up to 12 months [7]. Generic liraglutide exists too, as low as $20 through Teva's program for commercially insured patients [8]. If cost is deciding a teen's treatment, bring these numbers to your physician.

Key Takeaway

With commercial insurance, Wegovy can cost as little as $25 per month. Without insurance, NovoCare Pharmacy's self-pay price is $199 per month for your first two fills, then $349. You need only a valid prescription.

Wondering if you qualify?

Check Your Eligibility →

Zepbound Cost in 2026: LillyDirect Self-Pay and the Lilly Savings Card

If you are 18 or older, Zepbound (tirzepatide) belongs in your cost comparison; it is not approved for anyone under 18 [4]. At list price, pens run about $1,086 per fill [6]. With commercial insurance that covers it, the Zepbound Savings Card brings that to as low as $25 for a one-month or three-month supply of single-dose pens, with government beneficiaries excluded and savings limits applying [4] [6].

Without coverage, LillyDirect is Lilly's own channel for cash-paying patients, with free home delivery or Walmart pickup. After a December 2025 price cut, Zepbound vials and the KwikPen cost $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg doses [4] [9]. One catch: the $449 price requires refilling within 45 days, and missing that window pushes the price to as much as $699 or more per month [4] [9]. Set a refill reminder; it is worth hundreds of dollars. Also budget for needles or syringes, which the vials and KwikPen require separately [4].

83.2%

of appealed prior authorization denials in Medicare Advantage were fully or partially overturned in 2022, yet only about 1 in 10 denials were appealed [11]. The most underused money-saving tool in this guide is the appeal letter.

Patient Assistance Programs: Free Medication If You Qualify

If your household income is limited, both manufacturers run charitable programs that can provide medication at no cost. These are the most overlooked resources in the GLP-1 affordability conversation because people assume they will not qualify. Check anyway; the thresholds are higher than most expect.

The Novo Nordisk Patient Assistance Program (PAP) provides Novo Nordisk medicines free to eligible patients, with no fees and free home shipping [12]. To qualify in 2026, you must be a US citizen or legal resident, be uninsured or have Medicare (commercial insurance disqualifies you), not qualify for Medicaid, and have household income generally at or below 400% of the Federal Poverty Level [12]. Uninsured applicants are enrolled for 12 months, and complete applications are typically processed within two business days [12]. One caveat: the covered-medicines list was trimmed for 2026, so confirm your medication is on the current PAP product list before applying [12].

Eli Lilly's counterpart is the Lilly Cares Foundation, which provides prescribed Lilly medications free for up to 12 months to qualifying US patients [13]. It also has income limits and a defined medication list, and weight management coverage has historically been limited, so check lillycares.com first. If neither fits, NeedyMeds maintains a free database of assistance programs [12], and campus health centers can connect students with sliding-scale care and help complete the prescriber portions of applications.

Key Takeaway

If you are uninsured with household income at or below roughly 400% of the Federal Poverty Level, you may qualify for free medication through the Novo Nordisk PAP. Applications are free, decisions take about two business days, and enrollment lasts 12 months.

Denied by Insurance? How to Appeal and Win

In Medicare Advantage plans, 83.2% of appealed prior authorization denials were fully or partially reversed, yet only about one in ten denials were appealed [11], and ACA marketplace consumers appealed fewer than 1% of denied claims [14]. Insurers are counting on you to give up. Do not. A denial is usually a paperwork problem, and the fix is also paperwork.

  1. Get the denial in writing and read the reason. "Not medically necessary" is answered differently than "prior authorization required" or "plan exclusion."
  2. Confirm whether your plan covers weight management medications at all. If GLP-1s are excluded from the formulary, an appeal is unlikely to succeed; focus on self-pay pricing or ask the employer to add coverage using Novo Nordisk's sample coverage request letter [15].
  3. Ask your prescriber to file a prior authorization with complete clinical documentation. Strong submissions cover BMI (or BMI percentile for adolescents), conditions like prediabetes, high blood pressure, PCOS, or sleep apnea, prior weight management attempts, and the guideline basis for treatment.
  4. File an internal appeal within the deadline. Include a letter of medical necessity, labs and chart notes, and guideline citations. Deadlines are commonly 180 days but vary; check your denial letter.
  5. Escalate to external review if the internal appeal fails. Most plans must offer an independent external review, where a third party, not your insurer, makes the final call [16].

If you are on a parent's plan, the policyholder may need to join insurer calls, but the clinical documentation comes from your care team, and a physician-led program can take most of this off your plate.

The Cheapest Way to Get a GLP-1 Is Rarely the Riskiest Way

Type "cheapest way to get GLP-1" into a search bar and you will meet websites offering "semaglutide" at prices that undercut everything here. This is where we stop being budget advisors and start being clinicians.

Avoid compounded semaglutide from unregulated sources

Compounded GLP-1 drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality [17]. As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, including hospitalizations linked to dosing errors, plus fraudulent and counterfeit products in the US supply chain [17]. With the national shortage resolved, the legal basis for mass-market compounding has largely disappeared [18]. If a website offers steep discounts, skips a real medical evaluation, or claims its product is "the same as" an FDA-approved drug, the FDA considers those red flags, and so do we [17].

The math has changed, too. When compounded semaglutide took off, brand-name GLP-1s cost $1,000 or more per month in cash. In 2026, FDA-approved Wegovy starts at $199 per month for new self-pay patients and Zepbound at $299 [3] [4]. Saving a little is not worth injecting a product no regulator has verified, especially for anyone under 18. The cheapest safe path: insurance plus a savings card ($25), then patient assistance programs ($0 if you qualify), then manufacturer self-pay programs ($149 to $449 per month). Unregulated compounded products are not on that list at any price.

How Telehealth Programs Like Thryvwell Help You Navigate Cost

Everything above is doable on your own. But there are a lot of moving parts: savings cards, self-pay pharmacies, refill windows, assistance applications, prior authorizations, appeal deadlines. A good medical program manages that complexity with you.

Thryvwell is a physician-led, guideline-concordant telehealth program built for young people ages 12 to 26, overseen by our Chief Medical Officer, Dr. Glenda Pettaway. Clinically, that means evaluation by a licensed physician, eating disorder screening before any prescription, only FDA-approved medications, and ongoing nutrition and lifestyle support, with parents involved at every step for members under 18. On the cost side, our care team manages prior authorizations and supports appeals after denials. Coverage, savings-program eligibility, and pharmacy pricing are determined by the relevant insurer, manufacturer, and pharmacy.

Cost should never keep a young person who medically qualifies from treatment. Program pricing is straightforward and shared during your eligibility check, before any commitment. The check takes about 2 minutes, with no pressure.

Key Takeaway

You do not have to navigate GLP-1 costs alone. A physician-led telehealth program can manage prior authorizations and support appeals after denials as part of your care.

Frequently Asked Questions

How much is Wegovy without insurance in 2026?

Wegovy's list price is $1,349.02 per 28-day supply, but self-pay patients do not need to pay that [1]. Through NovoCare Pharmacy or the Wegovy Savings Offer, new self-pay patients pay $199 per month for their first two fills, then $349 per month for standard pen doses [3]. The Wegovy pill, adults only, starts at $149 per month [3].

What is the cheapest way to get a GLP-1 medication?

With commercial insurance that covers it, a savings card is cheapest: as little as $25 per month for Wegovy or Zepbound [3] [6]. If you are uninsured with limited income, a patient assistance program may provide medication free [12] [13]. Otherwise, manufacturer self-pay programs offer the lowest safe cash prices, from $149 per month [3] [4].

How much does Zepbound cost without insurance?

Through LillyDirect, Zepbound costs $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for higher doses with on-time refills [4] [9]. Outside that program, list price is about $1,086 per fill [6]. Zepbound is approved for adults only [4].

Can I get Wegovy for $25 a month?

Yes, if you have commercial (non-government) insurance that covers Wegovy. Enroll by texting SAVE to 83757 or through NovoCare's website, then present the offer at your pharmacy. Savings are capped at $100 per month [3].

What if my insurance denies coverage for a GLP-1?

Appeal. In Medicare Advantage, 83.2% of appealed prior authorization denials were fully or partially overturned, yet only about 1 in 10 denials were appealed [11]. Ask your physician to file a prior authorization with complete documentation, then use internal appeal and, if needed, external review [16].

Is compounded semaglutide a safe cheap alternative?

No. It is not FDA-approved or reviewed for safety, effectiveness, or quality, and the FDA has logged 990 adverse event reports for it as of May 2026 [17]. With FDA-approved options from $149 to $299 per month, the risk is not worth the savings [3] [4].

Do GLP-1 self-pay purchases count toward my insurance deductible?

No. Purchases through NovoCare Pharmacy or LillyDirect are processed outside your insurance and do not count toward your deductible or out-of-pocket maximum [3].

References

  1. Novo Nordisk. Saxenda and Wegovy List Price Information, NovoCare. Accessed July 2026.
  2. GoodRx. How Much Does Wegovy (Semaglutide) Cost Without Insurance? Accessed July 2026.
  3. Novo Nordisk. Savings Offer Program for Wegovy (semaglutide), NovoCare; What to Pay for Wegovy. Accessed July 2026.
  4. Eli Lilly and Company. Authentic Zepbound (tirzepatide) Shipped to You, LillyDirect. Accessed July 2026.
  5. U.S. Food and Drug Administration. Wegovy Approval Letter for Pediatric Patients Aged 12 Years and Older. December 23, 2022.
  6. Eli Lilly and Company. Zepbound Cost Information, Lilly Pricing Info. Accessed July 2026.
  7. Novo Nordisk. Saxenda (liraglutide) injection 3 mg: List Price, Savings, and Prescribing Information. Accessed July 2026.
  8. Teva Pharmaceuticals. Teva's Liraglutide Injection Savings Program. Accessed July 2026.
  9. Eli Lilly and Company. Lilly Lowers the Price of Zepbound (tirzepatide) Single-Dose Vials. Press release, December 1, 2025.
  10. Novo Nordisk. Wegovy (semaglutide) Online Pharmacy, NovoCare Pharmacy. Accessed July 2026.
  11. KFF / American Medical Association. Over 80% of Prior Auth Appeals Succeed. Why Aren't There More? October 2024.
  12. Novo Nordisk. Patient Assistance Program (PAP), NovoCare. Accessed July 2026.
  13. Lilly Cares Foundation. What Is Lilly Cares. Accessed July 2026.
  14. KFF. Claims Denials and Appeals in ACA Marketplace Plans in 2024. March 2026.
  15. Novo Nordisk. Wegovy Patient Coverage Request Sample Letter. Accessed July 2026.
  16. HealthCare.gov. How to Appeal an Insurance Company Decision. Accessed July 2026.
  17. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. June 2026.
  18. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Accessed July 2026.